Compare Revvity Inc (RVTY) vs Vistra Corp (VST) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Revvity Inc vs Vistra Corp — how do they compare? Revvity Inc trades at $124.14 (market cap $14.18B), while Vistra Corp trades at $151.01 (market cap $50.11B). The key difference: Vistra Corp is far larger — about 3.5× Revvity Inc's market cap, and Vistra Corp pays the higher dividend (0.62%). Which is the better fit depends on your goals.
| RVTY | VST | |
|---|---|---|
Market Cap | $14.18B | $50.11B |
Sector | Technology | Technology |
52-Week High | $130.94 | $217.92 |
52-Week Low | $82.26 | $134.71 |
Enterprise Value | $16.50B | $72.05B |
Dividend Yield | 0.22% | 0.62% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RVTY trades at $127.08, down 2.41% on the day, with a bullish technical signal from moving averages and strong support at $126. The company reported Q2 2026 EPS of $1.41, beating estimates, and raised its full-year outlook, driven by diagnostics strength and improved cash flow. Recent news includes the acquisition of Human Cell Design and the launch of the SuperFlex prenatal screening system.
Outlook is positive with 52% analyst buy ratings and a $135.25 consensus price target, implying ~6% upside. Risks include a premium valuation (P/E 61.1) and execution of growth initiatives. Strong institutional interest, such as Bank of New York Mellon's $78.77 million investment, supports confidence in the stock's trajectory.
Vistra Corp. (VST) trades at $151.72, up 1.62% today, with a bullish technical signal and strong analyst support. The stock shows mixed quarterly earnings but projects significant revenue and net income growth into 2026. Recent news highlights CEO and institutional buying, long-term power agreements with tech giants, and a consensus price target of $228.40, suggesting substantial upside potential from current levels.
The outlook is positive, driven by robust power demand, strategic partnerships, and a diversified generation fleet. Key risks include regulatory uncertainty and earnings volatility. With 91% of analysts rating it a buy and insider confidence, VST presents a compelling opportunity for growth-oriented investors, though market fluctuations and execution risks warrant caution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →About Vistra Corp
Vistra is a leading integrated retail electricity and power generation company that serves as a critical infrastructure provider for the digital economy. It operates a diversified portfolio of zero-carbon nuclear and renewable assets alongside a massive, flexible natural gas fleet, positioning it as an indispensable partner for energy-intensive AI data centers and industrial electrification.
Read more on VST →
